Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Drug Profile

Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Alternative Names: AT 1331; AT 1412; AT 1413; AT 1413 bivalent antibody immune therapeutic; AT 1628; AT 1630; AT 1636; AT-1219; AT-15226; AT-15260; AT-1613; AT-16201; AT1413 BAIT

Latest Information Update: 26 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AIMM Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Multiple myeloma; Solid tumours
  • Research Colorectal cancer; Liver cancer

Most Recent Events

  • 06 Sep 2017 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia and Myelodysplastic syndrome presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR - 2017)
  • 03 Aug 2017 Preclinical trials in Solid tumours in Netherlands (Parenteral) (AIMM Therapeutics pipeline, August 2017)
  • 01 Aug 2017 Merck & Co. acquires the license to AIMM Therapeutics' anti-cancer monoclonal antibody candidates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top